Impact of switching to injectables cabotegravir and rilpivirine on sleep disturbances in a cohort of people living with HIV

Figures & data

Table 1. Cohort description.

Characteristics	Overall (n = 46)
Age, median (IQR)	46 (41–57)
Gender, male, n (%)	35 (76.1)
Ethnicity, n (%)
Caucasian	36 (78.3)
Latin	5 (10.8)
Asian	3 (6.5)
Black-African	2 (4.4)
Level of education, n (%)
Low	35 (76.1)
High	9 (23.9)
Smoking status, n (%)
Never	32 (69.6)
Current smoker	12 (26)
Ex-smoker	2 (4.4)
Regular physical exercise, n (%)	17 (36.9)
Alcohol consumption, n (%)	3 (6.3)
Risk factor for HIV acquisition, n (%)
MSM	26 (56.5)
Heterosexuals	16 (34.7)
IVDU	10 (8.8)
Years living with HIV, median (IQR)	10 (5–19)
Previous AIDS events, n (%)	5 (10.8)
CD4+ at nadir, cell/mm^3, median (IQR)	360 (205–500)
CD4+ before switch, cell mm^3, median (IQR)	724 (524–894)
Antiretroviral regimen before switch, n (%)
TAF/FTC/RPV	18 (39.1)
DTG/3TC	15 (32.6)
ABC/3TC + NVP	3 (6.5)
TAF/FTC/BIC	2 (4.4)
DTG/RPV	2 (4.4)
TDF/3TC/DOR	1 (2.16)
ABC/3TC + EFV	1 (2.16)
TAF/FTC + RAL	1 (2.16)
DOR + DTG	1 (2.16)
DTG + ATV/r	1 (2.16)
TDF/FTC/RPV	1 (2.16)
Hepatitis coinfections, n (%)
HBV	0 (0)
HCV (eradicated)	3 (6.5)
Comorbidities, n (%)
Malignancies	2 (4.4)
Dyslipidemia	14 (30.4)
Lipodystrophy	4 (8.8)
Hypertension	9 (19.5)
Obesity	4 (8.8)
Diabetes	1 (2.1)
Osteoporosis	5 (10.8)
COPD	2 (4.4)
Anxiety/depression	7 (15.2)
Autoimmune disorders	3 (6.5)
Neurological diseases	2 (4.4)
Other comorbidities	18 (39.1)
Multimorbidity, n (%)	23 (50)
Polypharmacy, n (%)	6 (13)

Legend to Table 1: n = number, IQR = interquartile range, MSM = men who have sex with men, IVDU = intravenous drug use, COPD = chronic obstructive pulmonary disease, TAF/FTC/RPV = tenofovir alafenamide/emtricitabine/rilpivirine, DTG/3TC = dolutegravir/lamivudine, ABC/3TC + NVP = abacavir/lamivudine + nevirapine, TAF/FTC/BIC = tenofovir alafenamide/emtricitabine/bictegravir, DTG/RPV = dolutegravir/rilpivirine, TDF/3TC/DOR = tenofovir alafenamide/emtricitabine/doravirine, ABC/3TC + EFV = abacavir/lamivudine + efavirenz, TAF/FTC + RAL = tenofovir alafenamide/emtricitabine + raltegravir, DOR + DTG = doravirine/dolutegravir, DTG/ATV/r = dolutegravir + atazanavir/ritonavir, TDF/FTC/RPV = tenofovir disoproxil fumarate/emtricitabine/rilpivirine.

Table 2. Sleep metrics and results from screening for sleep disturbances at the baseline and at follow-up.

Item/parameter	Baseline, (n = 46)	Follow-up (n = 46)	P value
Sleep disorders*
Overall, n (%)
None	29 (63)	26 (56.5)	0.512
2 or more positive categories in BQ, n (%)	9 (19.5)	7 (15.2)	0.748
ISI >15, n (%)	6 (13)	4 (8.7)	0.739
ESS > 10, n (%)	7 (15.2)	2 (4.4)	0.157
PSQI> 5, n (%)	6 (13)	20 (43.5)	0.002
Parasomnia, n (%)	1 (2.2)	1 (2.2)	1
*Each patient may have more than one
Scoring for each questionnaire, median (IQR)
BQ score, median (IQR)	1 (0–2)	1 (1–2)	0.41
ISI score, median (IQR)	5 (3–7)	6 (3–7)	0.26
ESS score, median (IQR)	7 (5–8)	6 (5–8)	0.23
PSQI score, median (IQR)	4 (3–5)	7 (5–7)	0.001
Self-reported insomnia severity
None, n (%)	21 (45.6)	24 (52.2)	0.676
Mild, n (%)	12 (26.1)	17 (36.9)	0.369
Moderate, n (%)	8 (17.4)	3 (6.5)	0.197
Severe/extremely severe, n (%)	5 (10.9)	2 (4.4)	0.434
Self-reported snoring, n (%)	19 (41.3)	18 (39.1)	1
Sleeping hours per night, hours, median (IQR)	7 (6–8)	7.0 (7–8)	0.214
Time to fall asleep > 30 min, n (%)	12 (26)	10 (8.8)	0.807
Early awakening, n (%)	18 (39.1)	12 (26)	0.260
Issues in sleep maintenance, n (%)	21 (45.6)	11 (23.9)	0.048
Issues in falling asleep, n (%)	19 (41.3)	12 (26)	0.185
Afternoon nap (yes), n (%)	34 (73.9)	28 (60.9)	0.266
Overall use of hypno-inducing drugs, n (%)	4 (8.7)	6 (13)	0.739
Self-reported wellness (0–10), median (IQR)	8 (7–9)	8 (7–9)	0.388
How would you rate the overall quality of your sleep?
Improved	–	17 (37)	–
Unchanged	–	29 (63)	–
Worsened	–	0 (0)	–